OMS 405

Drug Profile

OMS 405

Alternative Names: OMS 403; OMS405

Latest Information Update: 10 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omeros Corporation
  • Developer New York State Psychiatric Institute; Omeros Corporation
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Opioid abuse; Smoking withdrawal
  • Preclinical Alcoholism

Most Recent Events

  • 16 Mar 2017 Preclinical development for Alcoholism is ongoing in the US
  • 16 Mar 2017 Omeros Corporation has patent protection for OMS 405 for addictive disorders in USA and ex-US countries
  • 02 Nov 2016 Pharmacodynamics data from a phase II trial in Opioid abuse released by Omeros
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top